TENCENT ANNOUNCES 2025 THIRD QUARTER RESULTS

Solid Revenue Growth with Continued Operating Leverage AI InvestmentsContributing to Business Growth and Efficiency Enhancement Tencent Holdings Limited (HKEX: 00700 (HKD Counter) and 80700 (RMB Counter), “Tencent” or “the Company”), a world-leading Internet and technology company in China, today announced the unaudited consolidated results for the quarter ended 30 September 2025 (“3Q2025”). Mr. Ma Huateng, […]

Gabriel Marketing Group Launches GEO Content Development Services for B2B Tech Brands in the Generative AI Era

Powered by Brandi AI, GMG's Generative Engine Optimization (GEO) content development services help make brand content more discoverable, understandable and citable by AI models such as ChatGPT, Google Gemini, Claude and Perplexity Gabriel Marketing Group (GMG), the leading public relations agency for high-growth B2B technology companies, today announced the launch of its enhanced content development

AtkinsRéalis Reports Third Quarter 2025 Results

— Total revenue of $2.8 billion, up 15% over Q3 2024 — AtkinsRéalis Services revenue(1) and Segment Adjusted EBIT(1) both up 17% — Diluted EPS from PS&PM of $0.84, up 68%, and Adjusted diluted EPS from PS&PM(2) of $1.06, up 68% over Q3 2024 — Net cash generated from operating activities of $123 million —

MolecuLight to Exhibit and Showcase New Consensus on Fluorescence Imaging in Surgical Wound Management at IPAWS Summit 2025

MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment, is proud to announce the publication of a landmark international consensus report, developed by leading experts in wound care and surgery from across the United States. The report, titled “Fluorescence imaging in surgical wound management: A consensus-based approach”, represents a pivotal step toward

mRNA Synthesis & Manufacturing Market Size to Hit USD 1.87 Billion by 2034

Ottawa, Nov. 13, 2025 (GLOBE NEWSWIRE) — The global mRNA synthesis & manufacturing market size is calculated at USD 1.55 billion in 2024, grows to USD 1.58 billion in 2025, and is projected to hit around USD 1.87 billion by 2034, growing at a CAGR of 1.9% from 2025 to 2034. mRNA Synthesis & Manufacturing

mRNA Synthesis & Manufacturing Market Size to Hit USD 1.87 Billion by 2034

mRNA Synthesis & Manufacturing Market Size to Hit USD 1.87 Billion by 2034 According to Nova One Advisor, the global mRNA synthesis & manufacturing market size is calculated at USD 1.58 billion in 2025 and is expected to be hit around USD 1.87 billion by 2034, growing at a compound annual growth rate (CAGR) of

Golia Dental Rebrands as Hamden Dental Arts Under the Leadership of Dr. Nishan Halim

Golia Dental, a trusted name in Hamden's dental care community for decades, has officially rebranded as Hamden Dental Arts under the leadership of Dr. Nishan Halim. The change honors the longstanding legacy of founder Dr. Robert Golia while ushering in a new era of modern, technology-driven dentistry. https://mma.prnewswire.com/media/2808434/Hamden_Dental_Arts_Logo.jpg Dr. Robert Golia, who cared for Hamden

Appcast to Host Live Webinar: “2026 Recruitment Marketing Trends that Will Redefine Hiring”

Appcast Chief Product Officer Matt Plummer will provide a sneak peek into the findings of Appcast's upcoming whitepaper, “Top Recruiting Trends of 2026” What: Appcast, the leading recruitment marketing platform powered by programmatic, will hold a live webinar hosted by Appcast Chief Product Officer Matt Plummer. He will provide an inside look at the recruiting

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

(NYSE MKT:SER), HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug (“IND”) candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform(TM) drug optimization technology, today announced its financial results for the third quarter ended

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights GlobeNewswire November 13, 2025 HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug (“IND”) candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ

Scroll to Top